πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,257 results for β€œFirst” Clear

  1. Recombinant NV-A01 adenovirus injection

    The First People's Hospital of Lianyungang

    Advanced Glioblastoma Patients

    phase 1 small molecule active

    1 trial

  2. Risperidone

    The First People's Hospital of Lianyungang

    Schizophrenia

    phase 1 small molecule active

    1 trial

  3. Ritonavir Tablet 100mg

    The First People's Hospital of Lianyungang

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  4. Ritonavir for cycle1 and NORVIR for cycle 2

    The First People's Hospital of Lianyungang

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  5. Rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma Recurrent

    phase 1 small molecule active

    1 trial

  6. SAR447971 first-in-human study

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 1 other active

    1 trial

  7. SCT510

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule completed

    1 trial

  8. SIG001

    The First People's Hospital of Lianyungang

    Neoplams

    phase 1 mab active

    1 trial

  9. SZ011 CAR-NK

    The First People's Hospital of Lianyungang

    Advanced Triple Negative Breast Cancer

    phase 1 small molecule active

    1 trial

  10. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  11. Salvianolic Acid A

    The First People's Hospital of Lianyungang

    Neuropathy of Diabetes

    phase 1 small molecule active

    1 trial

  12. Serine（OralοΌ‰

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 1 small molecule active

    1 trial

  13. Shenkang decoction

    The First People's Hospital of Lianyungang

    Chronic Renal Failure

    phase 1 small molecule completed

    1 trial

  14. Sonodynamic therapy (SDT)

    The First People's Hospital of Lianyungang

    Carotid Atherosclerosis

    phase 1 other completed

    1 trial

  15. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

    phase 1 mab active

    1 trial

  16. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  17. TALEN

    The First People's Hospital of Lianyungang

    Human Papillomavirus-Related Malignant Neoplasm

    phase 1 mab active

    1 trial

  18. TCR-T cells

    The First People's Hospital of Lianyungang

    Recurrent Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  19. TNP-2092 capsules

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    phase 1 small molecule completed

    1 trial

  20. TNX-1500

    Tonix Pharmaceuticals Holding

    Phase 1 First-in-human Study Involving Healthy Subjects

    phase 1 small molecule completed

    1 trial

  21. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  22. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  23. ThisCART19A with Dose Level 1

    The First People's Hospital of Lianyungang

    CAR

    phase 1 small molecule active

    1 trial

  24. ThisCART22 cells injection

    The First People's Hospital of Lianyungang

    B Cell Malignancy

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources